公开(公告)号：US20220403038A1

公开(公告)日：2022-12-22

申请号：US17775257

申请日：2020-11-09

Applicant: AMGEN INC.

Inventor： David John LLOYD ,  Elizabeth Ann KILLION ,  Glenn N. SIVITS, JR.

IPC: C07K16/28 ,  A61P3/00

Abstract: Methods of treating diseases and disorders characterized by elevated levels of cortisol using an antigen binding protein specific for the GIPR polypeptide are provided. In various embodiments the disease or disorder is Cushing's syndrome.

公开(公告)号：US20240084301A1

公开(公告)日：2024-03-14

申请号：US18357495

申请日：2023-07-24

Applicant: AMGEN INC.

Inventor： Elizabeth Ann KILLION ,  Jerry Ryan HOLDER ,  Bryan MEADE ,  Justin K. MURRAY ,  Oliver R. HOMANN ,  Briana Renee GRIEGO ,  Murielle Marie VENIANT ELLISON

IPC: C12N15/113 ,  A61P1/16 ,  A61P3/04

CPC classification number: C12N15/113 ,  A61P1/16 ,  A61P3/04 ,  C12N2310/14 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/322

Abstract: The present application relates to compositions and methods for modulating expression of Family with Sequence Similarity 13 Member A (FAM13A) protein. In particular, the present application relates to nucleic acid-based therapeutics for reducing FAM13A gene expression via RNA interference and methods of using such nucleic acid-based therapeutics to reduce abdominal adiposity, reduce body weight, reduce fat mass, improve metabolic parameters including insulin resistance and non-alcoholic steatohepatitis (NASH), and reduce risk of myocardial infarction.